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Purpose: To report the short term anatomical and visual acuity response after intravitreal 
injection of bevacizumab in patients with proliferative diabetic retinopathy.
Methods: Ten eyes having proliferative diabetic retinopathy were treated with at least one 
intravitreal injection of bevacizumab, 1.25 mg in 0.05 mL. Patients underwent complete 
ophthalmologic evaluation at baseline and follow up visits including Snellen’s best corrected 
visual acuity (BCVA), fundus biomicroscopy and ﬂ  uorescein angiography. Vitreous hemorrhage 
precluding laser treatment was present in 6 eyes.
Results: Follow up ranged between 3 and 6 months (mean 4.2 ± 1.23 months). Improvement of 
vision was observed after one week with BCVA improved to 0.47 ± 0.26 compared with baseline 
BCVA of 0.365 ± 0.26 (P  0.05). At last follow up, BCVA was 0.65 ± 0.33. Seven eyes had 
better visual acuity. Vitreous hemorrhage cleared completely in 4 eyes while 2 eyes had residual 
vitreous hemorrhage. Regression of retinal neovascularization was complete in 7 eyes, incom-
plete in 3 eyes. Regression was observed as early as 2 weeks after ﬁ  rst injection. Reperfusion 
after regression was observed in 2 eyes. Patients received a mean of 1.7 ± 0.67 injections per 
eye. No complications were noted in all eyes. Pancryopexy was done in 1 eye and additional 
laser was done in 2 eyes.
Conclusion: Intravitreal bevacizumab was safe and effective in treatment of proliferative 
diabetic retinopathy. It can induce effective regression of retinal neovascularization and rapid 
clearance of vitreous hemorrhage. It can be used as an adjunctive therapy with laser photo-
coagulation and to enhance absorption of vitreous hemorrhage with subsequent deferral from 
vitrectomy.
Summary: Ten eyes having proliferative diabetic retinopathy were treated with intravitreal 
bevacizumab. Following injection, evident regression of retinal neovascularization and rapid 
clearance of vitreous hemorrhage as well as vision improvement was observed.
Keywords: intravitreal bevacizumab, proliferative diabetic retinopathy, retinal neovasculariza-
tion, vascular endothelial growth factor, vitreous hemorrhage
Introduction
Diabetic retinopathy remains the leading cause of new blindness in young adults. 
Without treatment, 50% of those with proliferative disease will be blind within 
5 years (Chew 1999). Hyperglycemia induces retinal hypoxia that up regulates a 
range of vasoactive factors which may lead to macular edema and/or angiogenesis 
and hence potentially sight threatening retinopathy (Malik et al 2005). A generally 
accepted explanation of the ﬁ  bro-vascular proliferations found in proliferative diabetic 
retinopathy (PDR) is that widespread retinal ischemia leads to release of vasopro-
liferative factors such as vascular endothelial growth factor (VEGF) which diffuses 
through out the vitreous as well as the anterior segment inducing neovascularization 
(Wilkinson-Berka 2004). Vitreous levels of VEGF were elevated by approximately Clinical Ophthalmology 2007:1(2) 150
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3-fold in patients with advanced proliferative retinopathy 
(Malik et al 2005). Intraocular injection of VEGF causes 
micro vascular abnormalities and retinal ischemia (Tolentino 
et al 1996, 2002) Pan retinal laser photocoagulation (PRP) 
represents the main stay in the treatment of proliferative 
diabetic disease (DRSRG 1976, 1981). However, the laser 
therapy might be hindered by vitreous hemorrhage and or 
early cataract. Vitreous hemorrhage may be encountered in 
eyes having maximum laser therapy.
Intravitreal bevacizumab (Avastin, Genentech Inc., 
San Francisco, CA), a full length humanized monoclonal 
antibody to VEGF which was approved by the Food and 
Drug Administration for the treatment of colorectal cancer 
(Manzano et al 2006). It can inhibit both types of VEGF 
receptors: VEGFR-1 and VEGFR-2 (Manzano et al 2006). It 
has been recently shown to enhance the clearance of vitreous 
hemorrhage and induce involution of retinal neovasculariza-
tion with no reported complications (Avery 2006; Davidorf 
et al 2006; Spaide and Fisher 2006). It has been also tried in 
the treatment of macular edema due to central retinal vein 
occlusion (Iturralde et al 2006).
In this series of cases, intravitreal bevacizumab was 
offered aiming at enhancing the absorption of vitreous 
hemorrhage with possible deferral from vitrectomy and 
possible laser addition and inducing regression of retinal 
neovascularization persistent after having maximum PRP 
with the aim of reducing the morbidity of PDR. This report 
describes the short term results that a series of eyes with PDR 
had to intravitreal bevacizumab.
Methods
This work was done in Magrabi Eye Hospital in Muscat, 
Sultanate of Oman, after approval from the ethical commit-
tee and a written informed consent from the patients. The 
study included 10 eyes with proliferative diabetic retinopathy 
which were treated with at least one intravitreal injection of 
bevacizumab (Avastin, Genentech); 1.25 mg in 0.05 mL. 
Indications for Avastin injection were:
1.  Diabetic vitreous hemorrhage precluding laser treatment 
persistent for at least 3 months (6 eyes).
2.  Failure to induce complete regression of retinal neo-
vascularization after performing complete PRP with no 
apparent untreated retinal areas (4 eyes).
Cases with signiﬁ  cant tractional retinal detachment were 
not included in the study.
Patients were exposed to complete ophthalmologic evalu-
ation at base line and follow up visits including Snellen’s 
best corrected visual acuity, fundus biomicroscopy and 
ﬂ  uorescein angiography. After informed consent, 1.25 mg in 
0.05 mL bevacizumab was injected intravitreally under com-
plete sterile preparation in the operating theater in the usual 
sterile fashion (Aiello et al 2004) using topical anesthesia. 
Prophylactic topical antibiotic (gatiﬂ  oxacine) was given for 
2 days post-injection. Patients were followed up after one 
week, one month, and then monthly thereafter. Reinjection 
was considered after at least one month of the ﬁ  rst injection 
on a case by case basis. Laser treatment or cryopexy for 
anterior retina was given after clearance of the hemorrhage 
on individual basis. The main outcome measurements were 
visual acuity improvement, clearance of vitreous hemorrhage, 
regression of neovascularization on ﬂ  uorescein angiography, 
and complications related to injection or to the drug.
Statistical analysis
Values were expressed as mean ± standard deviation. Paired 
samples t test was used to compare visual acuity changes. 
P  0.05 was considered statistically signiﬁ  cant.
Results
Follow up period ranged between 3 and 6 months with mean 
follow up of 4.2 ± 1.23 months.
Baseline characteristics
A total of 10 eyes from 8 patients were reviewed. The 
patients included 5 males and 3 females with an average 
age 45.3 ± 13 years (range between 23 and 59 years). Four 
patients had type 1 diabetes and 4 had type 2 diabetes. All 
eyes had previous PRP; which was complete in 7 eyes and 
insufﬁ  cient in 3 eyes. Vitreous hemorrhage precluding laser 
treatment was present in 6 eyes while in the other 4 eyes, 
maximum laser therapy was not able to induce regression of 
retinal neovascularization. One eye had clinically signiﬁ  cant 
macular edema. Two eyes were pseudophakic. Mean baseline 
best corrected visual acuity (BCVA) was 0.365 ± 0.26.
Improvement of vision (Figure 1) was observed after one 
week with mean BCVA improved to 0.47 ± 0.26, a differ-
ence from baseline that was signiﬁ  cant (P  0.05). Of the 
10 eyes, six eyes improved 2 lines or more, 1 eye acquired 
1 line while 3 eyes kept the same baseline vision. Only in 
1 eye, visual improvement was ascribed to improvement of 
macular edema. The visual improvement was maintained 
till the end of follow up. After one month, mean BCVA was 
0.555 ± 0.32. At last follow up, Mean BCVA was 0.65 ± 
0.33. The improvement of vision was statistically signiﬁ  cant 
at all post injection evaluation points in comparison to the 
baseline (P  0.05).Clinical Ophthalmology 2007:1(2) 151
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Out of 6 eyes having vitreous hemorrhage, 4 eyes had 
complete clearance of hemorrhage between 4 and 8 weeks, 
while 2 eyes had incomplete clearance with residual vitre-
ous hemorrhage (Figures 2 and 3). Signiﬁ  cant reduction of 
leakage was observed in angiography as early as 2 weeks 
after injection. Regression of retinal neovascularization 
was complete in 7 eyes (70%) within 4 to 8 weeks using 
1 to 2 injections (Figures 2 and 3). Three eyes had signiﬁ  -
cant, however, incomplete regression of neovascularization. 
Reperfusion after regression was observed in 2 eyes, 3 and 4 
months from the ﬁ  rst injection (Figures 3 and 4). Re-bleeding 
occurred in one eye in association with reperfusion. Reper-
fusion regressed 2 weeks after re-injection in both cases. 
Six eyes (60%) required more than one injection. Frequency 
of injections per eye ranged between 1 to 3 injections with 
a mean value of 1.7 ± 0.67. Reasons for repeated injection 
were reperfusion in one case, reperfusion plus re-vitreous 
hemorrhage in one case and incomplete regression of vitre-
ous hemorrhage and/or neovascularization in 4 cases. A total 
of 17 bevacizumab injections were performed in the whole 
work at the end of follow up period. No ocular or systemic 
adverse events were noted during the follow up period 
including endophthalmitis, clinically evident inﬂ  ammation, 
rise of intraocular pressure, rhegmatogenuos retinal detach-
ment and systemic thrombo-embolic events. No progres-
sion to tractional detachment was observed. Pancryopexy 
to the anterior retina was done in one eye (previously had 
maximum PRP) and additional laser was done in 2 eyes. 
Additional procedures were all performed after 3 months 
following the ﬁ  rst injection.
Discussion
Retinal neovascularization and macular edema are central 
features of diabetic retinopathy, a major cause of blindness 
in working age adults. The currently established treatment 
for diabetic retinopathy targets the vascular pathology by 
laser photocoagulation (Caldwell et al 2005). According 
to diabetic retinopathy study (DRSRG 1976, 1981), PRP 
reduced the risk of severe vision loss by more than 50%. 
This approach is associated with signiﬁ  cant adverse effects 
due the destruction of neural tissue and is not always 
effective.
Characterization of the molecular and cellular processes 
involved in vascular growth and hyper permeability has led 
to the recognition that the angiogenic growth factor and 
vascular permeability factor VEGF plays a pivotal role in 
the retinal microvascular complications of diabetes. Thus, 
VEGF represents an important target for therapeutic inter-
vention in diabetic retinopathy. Agents that directly inhibit 
the actions of VEGF and its receptors show considerable 
promise (Caldwell et al 2005). Pegaptanib (Macugen) has 
been reported to cause involution of retinal neovasculariza-
tion (MDRSG 2006).
In the current series, bevacizumab intravitreal injection 
was followed by rapid improvement of vision as early as 
one week following injection. This reﬂ  ects rapid clearance 
Figure 1 shows improvement of vision following bevacizumab injection which is maintained up to the end of follow up.
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of vitreous hemorrhage. It reﬂ  ects improvement of macular 
edema only in one eye not associated with vitreous hem-
orrhage. Vitreous hemorrhage cleared either completely 
or signiﬁ  cantly resulted in improvement of vision which 
lasted up to the end of follow up. Clearance of media opac-
ity precluding PRP has also made additional laser possible. 
Vitrectomy, the therapeutic modality in cases with persistent 
vitreous bleeding, could be avoided. Regression of retinal 
neovascularization was observed as early as 2 weeks. Avery 
(2006) reported regression in 1 case 1 week following 
intravitreal bevacizumab. Complete regression in this work 
was achieved in 70% of eyes. Avery and colleagues (2006) 
reported complete resolution of retinal neovascularization 
in 73% of cases. Spaide and Fisher (2006) reported on 
2 cases with improvement of vision as early as 1 week after 
bevacizumab injection. Spaide and Fisher (2006) suggested a 
mechanism to explain this rapid clearance of vitreous hemor-
rhage. They suggested that persistent diabetic bleeding is due 
to repeated attacks of bleeding as the vitreous hemorrhage 
keeps its red coloration all the time, so involution of neo-
vessels results in stoppage of new attacks of bleeding while 
the absorption process clears the preexisting blood. This 
signiﬁ  cant absorption of blood within one week is relatively 
rapid. The author believes that bevacizumab might have an 
enhancing effect on the absorption of blood but the mecha-
nism is not clear.
Reperfusion was observed in 2 cases in the current series 
3 and 4 months after ﬁ  rst injection. Avery and colleagues 
(2006) reported leakage recurrence as early as 2 weeks and as 
late as 11 weeks. Spaide and Fisher (2006) reported reperfu-
sion in one case 3 months after injection which responded 
to re-injection. In the current series, reperfusion regressed 
2 weeks after re-injection. Reperfusion means that the effect 
obtained by bevacizumab might be short term and explains 
the need for repeated injection and or additional proce-
dures (laser or cryopexy) to stabilize bevacizumab induced 
Figure 2 This 53 years old patient presented with dense vitreous hemorrhage obscuring fundus details 4 months after having intensive laser therapy. One month after ﬁ  rst 
bevacizumab injection, (A) Fundus details could be partially seen due to starting absorption of the blood and (B) the angiogram showed NVD. C, One month after second 
bevacizumab injection, the blood was completely absorbed and the angiogram (D) showed complete regression of the NVD.
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regression. It has been reported that bevacizumab has half 
life time of 4.32 days in the vitreous cavity of phakic rabbits 
and expected to last in the vitreous cavity approximately for 
22 days (Bakri et al 2006). A single dose was found to provide 
complete VEGF blockade for a minimum of 4 weeks with an 
intravitreal half life of unbound bevacizumab between 2 and 
6 days (Beer et al 2006). Reperfusion is because bevacizumab 
blocks the VEGF already secreted in the vitreous cavity but 
further secretion from the ischemic retina will continue. It 
has been reported that a high VEGF level was maintained in 
the vitreous cavity even after vitrectomy for PDR (Itakura 
et al 2004). The author believes that several factors play a 
role in the persistence of bevacizumab induced regression 
which include the severity of retinal ischemia, the activity of 
Figure 3 A 40 years old patient with PDR and vitreous hemorrhage (A). B,The ﬂ  uorescein angiogram showed evident neovascularization at the disc (NVD) with evident 
nasal ischemia. C, One month following bevacizumab injection there was near complete absorption of vitreous hemorrhage with a ﬁ  brous tuft arising from the optic disk 
(arrow).   The macula looks dry with marks of previous grid.   The angiogram (D) showed near complete regression of the neovascularization. E, three months following single 
injection, the angiogram showed evidence of reperfusion of NVD. F, 2 weeks following re-injection, the angiogram showed again complete regression of the NVD.
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Figure 4 This 43 years old patient presented with mild vitreous hemorrhage and preretinal hemorrhage 3 months after complete PRP.  A, showed NVDs on the disk and 
a tuft of neovessels nasal to the disk (arrows). NVE on the upper arcade are not shown in the color photo. He had visual acuity of 0.6. One month after ﬁ  rst bevacizumab 
injection, (B) showed better visualization of the retinal details and regression of NVDs on the disk and (C) the angiogram showed no NVD on the disk with residual 
leakage from NVE on the upper arcade (arrows) and NVD nasal to the disk.   There is upper macular intraretinal leakage (edema).The central macula however was dry. He 
was given a second injection. Six weeks after 2nd injection, D, angiogram showed residual activity of NVE on the upper arcade and nasal to the disk but no vessels on the 
disk. After 4 months from 1st injection, re-vitreous hemorrhage was observed. E, angiogram showed reperfusion of NVDs on and nasal to the disk and NVE on the upper 
arcade. A 3rd injection was given. F&G,4 weeks after injection, angiogram showed disappearance of NVD and NVE. Final visual acuity was 0.9. Cryopexy to the anterior 
retina was done to stabilize the ﬁ  nal outcome. 
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PDR and the extent of previous PRP. This therapeutic effect, 
despite being short term, seems effective in changing the 
sequence of events in cases of diabetic vitreous hemorrhage 
leading to rapid functional improvement with subsequent 
deferral from vitrectomy. In this series, no progression of 
tractional element of the ﬁ  brovascular tissue nor progression 
of tractional detachment was observed. Spaide and Fisher 
(2006) reported localized tractional retinal detachment in 
one case which did not change one month after bevacizumab 
injection. However, Arevalo and colleagues (2006) reported 
on 1 eye out of 25 eyes treated with bevacizumab in which 
PDR progressed to tractional retinal detachment requiring 
vitrectomy. This means that there is a risk of progression of 
tractional detachment in some cases which requires close 
follow up after bevacizumab injection. Intravitreal bevaci-
zumab showed positive biological effect in treatment of PDR 
with no safety concerns at least for the short term but long 
term safety and efﬁ  cacy could not be predicted according to 
the results of this study being non randomized, uncontrolled 
and retrospective with relatively short term follow up. Further 
research is warranted based on the accumulating reports sup-
porting similar ﬁ  ndings.
Intravitreal bevacizumab was effective in treatment of 
proliferative diabetic retinopathy without safety concerns. 
It can induce effective regression of retinal neovasculariza-
tion and rapid clearance of vitreous hemorrhage. It can be 
used as an adjunctive therapy with laser photocoagulation 
and to enhance absorption of vitreous hemorrhage with 
subsequent deferral from vitrectomy.
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